You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParoxetine
Accession NumberDB00715
TypeSmall Molecule
GroupsApproved, Investigational
Description

Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.

Structure
Thumb
Synonyms
(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
Paroxetina
Paroxetine
Paroxetinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Paroxetinetablet30 mgoralActavis Pharma Company2005-03-14Not applicableCanada
Act Paroxetinetablet20 mgoralActavis Pharma Company2005-03-14Not applicableCanada
Act Paroxetinetablet10 mgoralActavis Pharma Company2005-03-14Not applicableCanada
Auro-paroxetinetablet10 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetinetablet30 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetinetablet20 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Bio-paroxetinetablet20 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-paroxetinetablet10 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-paroxetinetablet30 mgoralBiomed PharmaNot applicableNot applicableCanada
Brisdellecapsule7.5 mg/1oralNOVEN THERAPEUTICS, LLC2013-06-28Not applicableUs
Dom-paroxetinetablet30 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-paroxetinetablet20 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-paroxetinetablet40 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-paroxetinetablet10 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Ipg-paroxetinetablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-paroxetinetablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-paroxetinetablet30 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-paroxetinetablet30 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-paroxetinetablet20 mgoralJamp Pharma Corporation2011-10-24Not applicableCanada
Jamp-paroxetinetablet10 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Mar-paroxetinetablet30 mgoralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mar-paroxetinetablet10 mgoralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mar-paroxetinetablet20 mgoralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mint-paroxetinetablet20 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-paroxetinetablet10 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-paroxetinetablet30 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mylan-paroxetinetablet30 mgoralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Mylan-paroxetinetablet20 mgoralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Mylan-paroxetinetablet10 mgoralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Ntp-paroxetinetablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-paroxetinetablet30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-paroxetinetablet20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-paroxetinetablet30 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-paroxetinetablet20 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-paroxetinetablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
Paroxetinetablet30 mgoralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
Paroxetinetablet20 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Paroxetinetablet20 mgoralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
Paroxetinetablet10 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Paroxetinetablet10 mgoralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
Paroxetinetablet30 mgoralSanis Health Inc2009-10-22Not applicableCanada
Paroxetinetablet20 mgoralSanis Health Inc2009-10-22Not applicableCanada
Paroxetinetablet30 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Paroxetinetablet10 mgoralSanis Health Inc2009-10-22Not applicableCanada
Paroxetinetablet30 mgoralMeliapharm Inc2004-04-062014-06-25Canada
Paroxetinetablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Paroxetinetablet20 mgoralMeliapharm Inc2004-04-062014-06-25Canada
Paroxetinetablet10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Paroxetinetablet30 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Paroxetinetablet10 mgoralMeliapharm Inc2004-04-062014-06-25Canada
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release37.5 mg/1oralApotex Corp2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralApotex Corp2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralApotex Corp2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release37.5 mg/1oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine-10tablet10 mgoralPro Doc Limitee2004-03-19Not applicableCanada
Paroxetine-20tablet20 mgoralPro Doc Limitee2004-03-19Not applicableCanada
Paroxetine-30tablet30 mgoralPro Doc Limitee2004-03-19Not applicableCanada
Paxiltablet, film coated40 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated30 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated20 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated30 mg/1oralPhysicians Total Care, Inc.1996-07-10Not applicableUs
Paxiltablet, film coated10 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated20 mg/1oralPhysicians Total Care, Inc.2006-09-18Not applicableUs
Paxilsuspension10 mg/5mLoralApotex Corp2011-01-01Not applicableUs
Paxil CRtablet, film coated, extended release12.5 mg/1oralSTAT Rx USA LLC2002-04-09Not applicableUs
Paxil CRtablet, film coated, extended release25 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxil CRtablet (extended-release)37.5 mgoralGlaxosmithkline IncNot applicableNot applicableCanada
Paxil CRtablet (extended-release)25 mgoralGlaxosmithkline Inc2004-01-05Not applicableCanada
Paxil CRtablet (extended-release)12.5 mgoralGlaxosmithkline Inc2004-01-05Not applicableCanada
Paxil CRtablet, film coated, extended release25 mg/1oralRebel Distributors Corp2002-04-09Not applicableUs
Paxil CRtablet, film coated, extended release12.5 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxil CRtablet, film coated, extended release37.5 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxil CRtablet, film coated, extended release12.5 mg/1oralRebel Distributors Corp2002-04-09Not applicableUs
Paxil Tab 10mgtablet10 mgoralGlaxosmithkline Inc1997-01-31Not applicableCanada
Paxil Tab 20mgtablet20 mgoralGlaxosmithkline Inc1993-12-31Not applicableCanada
Paxil Tab 30mgtablet30 mgoralGlaxosmithkline Inc1993-12-31Not applicableCanada
Paxilcr CRtablet, film coated, extended release12.5 mg/1oralPhysicians Total Care, Inc.2005-07-06Not applicableUs
Paxilcr CRtablet, film coated, extended release25 mg/1oralPhysicians Total Care, Inc.2003-05-16Not applicableUs
Paxilcr CRtablet, film coated, extended release37.5 mg/1oralPhysicians Total Care, Inc.2005-07-21Not applicableUs
Pexevatablet, film coated10 mg/1oralREMEDYREPACK INC.2016-02-23Not applicableUs
Pexevatablet, film coated40 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
Pexevatablet, film coated30 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
Pexevatablet, film coated20 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
Pexevatablet, film coated10 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
PMS-paroxetinetablet40 mgoralPharmascience Inc2007-05-03Not applicableCanada
PMS-paroxetinetablet30 mgoralPharmascience Inc2003-10-29Not applicableCanada
PMS-paroxetinetablet20 mgoralPharmascience Inc2003-10-29Not applicableCanada
PMS-paroxetinetablet10 mgoralPharmascience Inc2003-10-29Not applicableCanada
Priva-paroxetinetablet30 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-paroxetinetablet20 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-paroxetinetablet10 mgoralPharmapar IncNot applicableNot applicableCanada
Q-paroxetinetablet10 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Q-paroxetinetablet30 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Q-paroxetinetablet20 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Ratio-paroxetinetablet30 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Ratio-paroxetinetablet20 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Ratio-paroxetinetablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Riva-paroxetinetablet30 mgoralLaboratoire Riva Inc2004-02-16Not applicableCanada
Riva-paroxetinetablet20 mgoralLaboratoire Riva Inc2004-02-16Not applicableCanada
Riva-paroxetinetablet10 mgoralLaboratoire Riva Inc2004-02-16Not applicableCanada
Sandoz Paroxetinetablet10 mgoralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz Paroxetinetablet30 mgoralSandoz Canada Incorporated2004-09-212012-02-20Canada
Sandoz Paroxetinetablet20 mgoralSandoz Canada Incorporated2004-09-212012-02-20Canada
Sandoz Paroxetinetablet30 mgoralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz Paroxetinetablet20 mgoralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz Paroxetine Tabletstablet30 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Paroxetine Tabletstablet20 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Paroxetine Tabletstablet10 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Teva-paroxetinetablet20 mgoralTeva Canada Limited2004-01-16Not applicableCanada
Teva-paroxetinetablet10 mgoralTeva Canada Limited2004-01-16Not applicableCanada
Teva-paroxetinetablet30 mgoralTeva Canada Limited2004-01-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-paroxetinetablet30 mgoralApotex Inc2003-10-24Not applicableCanada
Apo-paroxetinetablet20 mgoralApotex Inc2003-10-24Not applicableCanada
Apo-paroxetinetablet10 mgoralApotex Inc2003-10-24Not applicableCanada
Paroxetinetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-10-31Not applicableUs
Paroxetinetablet30 mg/1oralInternational Laboratories, Inc.2007-12-11Not applicableUs
Paroxetinetablet, film coated40 mg/1oralProficient Rx LP2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2010-06-07Not applicableUs
Paroxetinetablet, film coated30 mg/1oralDIRECT RX2015-01-01Not applicableUs
Paroxetinetablet, film coated40 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated40 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2005-11-07Not applicableUs
Paroxetinetablet, film coated40 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-03-24Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-03-11Not applicableUs
Paroxetinetablet10 mg/1oralInternational Laboratories, Inc.2007-12-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-20Not applicableUs
Paroxetinetablet30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralbryant ranch prepack2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet10 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated40 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPhysicians Total Care, Inc.2008-10-15Not applicableUs
Paroxetinetablet, film coated30 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated30 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAidarex Pharmaceuticals LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Paroxetinetablet, film coated40 mg/1oralClinical Solutions Wholesale2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralProficient Rx LP2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCardinal Health2010-06-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Paroxetinetablet, film coated30 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated30 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated40 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated40 mg/1oralPhysicians Total Care, Inc.2009-02-18Not applicableUs
Paroxetinetablet, film coated20 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAidarex Pharmaceuticals LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Paroxetinetablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated30 mg/1oralClinical Solutions Wholesale2009-12-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralProficient Rx LP2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCardinal Health2004-02-14Not applicableUs
Paroxetinetablet, film coated20 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated30 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2011-08-16Not applicableUs
Paroxetinetablet, film coated20 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated40 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralTYA Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralSTAT Rx USA LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralClinical Solutions Wholesale2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-06-02Not applicableUs
Paroxetinetablet, film coated40 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2004-02-14Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralApotheca Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralH.J. Harkins Company, Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated20 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-06-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCardinal Health2011-05-19Not applicableUs
Paroxetinetablet, film coated10 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated40 mg/1oralDIRECT RX2016-02-29Not applicableUs
Paroxetinetablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Paroxetinetablet, film coated30 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralTYA Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralTeva Pharmaceuticals USA Inc2005-11-02Not applicableUs
Paroxetinetablet, film coated20 mg/1oralSTAT Rx USA LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMylan Institutional Inc.2005-12-26Not applicableUs
Paroxetinetablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet40 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-05-20Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated20 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-10-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMed Vantx, Inc.2005-10-03Not applicableUs
Paroxetinetablet, film coated40 mg/1oralBlenheim Pharmacal, Inc.2014-02-06Not applicableUs
Paroxetinetablet, film coated10 mg/1oralH.J. Harkins Company, Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-04-14Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2011-01-14Not applicableUs
Paroxetinetablet, film coated40 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMc Kesson Contract Packaging2011-09-16Not applicableUs
Paroxetinetablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralbryant ranch prepack2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralTeva Pharmaceuticals USA Inc2005-11-02Not applicableUs
Paroxetinetablet, film coated20 mg/1oralBlenheim Pharmacal, Inc.2014-02-06Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet30 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated40 mg/1oralSt. Mary's Medical Park Pharmacy2015-06-11Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated40 mg/1oralPd Rx Pharmaceuticals, Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2004-08-17Not applicableUs
Paroxetinetablet, film coated40 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated40 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2013-02-04Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-12-05Not applicableUs
Paroxetinetablet20 mg/1oralInternational Laboratories, Inc.2007-12-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated20 mg/1oralProficient Rx LP2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2007-04-132016-02-25Us
Paroxetinetablet, film coated20 mg/1oralbryant ranch prepack2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet10 mg/1oralREMEDYREPACK INC.2011-04-18Not applicableUs
Paroxetinetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-03-24Not applicableUs
Paroxetinetablet, film coated40 mg/1oralREMEDYREPACK INC.2014-04-10Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2011-05-19Not applicableUs
Paroxetinetablet, film coated30 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-20Not applicableUs
Paroxetinetablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralbryant ranch prepack2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Paroxetinetablet, film coated20 mg/1oralTeva Pharmaceuticals USA Inc2005-10-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralUnit Dose Services2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet20 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated20 mg/1oralSt. Mary's Medical Park Pharmacy2015-06-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2004-04-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated30 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-03-29Not applicableUs
Paroxetine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2011-11-03Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-07-21Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release37.5 mg/1oralMylan Pharmaceuticals Inc.2011-05-05Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralPhysicians Total Care, Inc.2008-05-23Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-07-11Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralMylan Pharmaceuticals Inc.2008-05-14Not applicableUs
Paroxetine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2011-06-17Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralPhysicians Total Care, Inc.2010-10-25Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralMylan Pharmaceuticals Inc.2008-05-14Not applicableUs
Paroxetine Hydrochloridetablet30 mg/1oralREMEDYREPACK INC.2011-06-16Not applicableUs
Paroxetine Hydrochloridetablet40 mg/1oralREMEDYREPACK INC.2011-06-07Not applicableUs
Paroxetine Hydrochloride Anhydroustablet, film coated20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AropaxNot Available
PAXILCRNot Available
SereupinNot Available
SeroxatNot Available
Seroxat CRNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paroxetine hydrochloride
Thumb
  • InChI Key: GELRVIPPMNMYGS-RVXRQPKJSA-N
  • Monoisotopic Mass: 365.119399455
  • Average Mass: 365.826
DBSALT000132
Paroxetine hydrochloride hemihydrate
ThumbNot applicableDBSALT001742
Paroxetine mesylate
Thumb
  • InChI Key: SHIJTGJXUHTGGZ-RVXRQPKJSA-N
  • Monoisotopic Mass: 425.1308364
  • Average Mass: 425.471
DBSALT000133
Categories
UNII41VRH5220H
CAS number61869-08-7
WeightAverage: 329.3654
Monoisotopic: 329.142721716
Chemical FormulaC19H20FNO3
InChI KeyInChIKey=AHOUBRCZNHFOSL-YOEHRIQHSA-N
InChI
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
IUPAC Name
(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
SMILES
FC1=CC=C(C=C1)[C@@H]1CCNC[[email protected]]1COC1=CC2=C(OCO2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Benzodioxole
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Oxacycle
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationLabeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.
PharmacodynamicsParoxetine, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type, has no active metabolites and has the highest specificity for serotonin receptors of all the SSRIs. It is used to treat depression resistant to other antidepressants, depression complicated by anxiety, panic disorder, social and general anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder, premature ejaculation, and hot flashes of menopause in women with breast cancer. In human platelets, paroxetine blocks the uptake of serotonin. It has weak effects on norepinephrine and dopamine neuronal reuptake. In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors.
Mechanism of actionParoxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.
Related Articles
AbsorptionParoxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.
Volume of distribution

3.1-28 L/kg observed in animal studies. Paroxetine distributes throughout the body, including the central nervous system, with only 1% remaining in the plasma.

Protein binding~ 95% bound to plasma proteins.
Metabolism

Paroxetine is extensively metabolized after oral administration, likely in the liver. The main metabolites are polar and conjugated products of oxidation and methylation, which are readily eliminated by the body. The predominant metabolites are glucuronic acid and sulfate conjugates. Paroxetine metabolites do not possess significant pharmacologic activity (less than 2% that of parent compound). Paroxetine is metabolized by cytochrome P450 (CYP) 2D6. Enzyme saturation appears to account for the nonlinear pharmacokinetics observed with increasing dose and duration of therapy.

Route of eliminationApproximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites. Approximately 36% of the dose was excreted in the feces (via bile), mostly as metabolites and less than 1% as parent compound.
Half life21-24 hours
ClearanceNot Available
ToxicityLD50=500mg/kg (orally in mice). Symptoms of overdose include: coma, dizziness, drowsiness, facial flushing, nausea, sweating, tremor, vomiting. Side effects include: nervous system effects such as asthenia, somnolence, dizziness, insomnia, tremor, and nervousness; GI effects such as nausea, decreased appetite, constipation, diarrhea, and dry mouth; impotence, ejaculatory dysfunction (principally ejaculatory delay), and other male genital disorders; female genital disorders (principally anorgasmia or difficulty reaching climax/orgasm); and sweating. Discontinuation syndrome may occur with abrupt withdrawal. Symptoms of discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory changes, and hyperactivity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableC AlleleC Allele potentially associated with discontinuation syndrome in patients treated for anxiety or depression.20075642
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9869
Caco-2 permeable+0.5195
P-glycoprotein substrateSubstrate0.6555
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.6771
Renal organic cation transporterInhibitor0.5222
CYP450 2C9 substrateNon-substrate0.9265
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6004
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.8298
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8649
Ames testNon AMES toxic0.6722
CarcinogenicityNon-carcinogens0.9046
BiodegradationNot ready biodegradable0.995
Rat acute toxicity2.8239 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5554
hERG inhibition (predictor II)Non-inhibitor0.5879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Mylan pharmaceuticals inc
  • Actavis elizabeth llc
  • Alphapharm pty ltd
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Noven therapeutics llc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral7.5 mg/1
Tabletoral10 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral40 mg/1
Tabletoral20 mg/1
Tabletoral30 mg/1
Tabletoral40 mg/1
Suspensionoral10 mg/5mL
Tablet (extended-release)oral12.5 mg
Tablet (extended-release)oral25 mg
Tablet (extended-release)oral37.5 mg
Tablet, film coated, extended releaseoral12.5 mg/1
Tablet, film coated, extended releaseoral25 mg/1
Tabletoral10 mg
Tabletoral20 mg
Tabletoral30 mg
Tablet, film coated, extended releaseoral37.5 mg/1
Tabletoral40 mg
Prices
Unit descriptionCostUnit
Paxil 30 40 mg tablet Bottle138.39USD bottle
Paxil 30 30 mg tablet Bottle131.0USD bottle
Paxil 30 10 mg tablet Bottle121.87USD bottle
Pexeva 40 mg tablet6.29USD tablet
Pexeva 30 mg tablet6.11USD tablet
Pexeva 20 mg tablet5.84USD tablet
Pexeva 10 mg tablet5.6USD tablet
Paxil CR 37.5 mg 24 Hour tablet4.5USD tablet
Paxil 40 mg tablet4.44USD tablet
Paxil CR 25 mg 24 Hour tablet4.37USD tablet
Paxil cr 37.5 mg tablet4.32USD tablet
Paxil 30 mg tablet4.2USD tablet
Paxil cr 25 mg tablet4.2USD tablet
Paxil CR 12.5 mg 24 Hour tablet4.18USD tablet
Paxil 20 mg tablet4.16USD tablet
PARoxetine HCl 37.5 mg 24 Hour tablet4.04USD tablet
Paxil cr 12.5 mg tablet4.02USD tablet
PARoxetine HCl 25 mg 24 Hour tablet3.93USD tablet
Paxil 10 mg tablet3.91USD tablet
PARoxetine HCl 12.5 mg 24 Hour tablet3.76USD tablet
Paroxetine hcl 40 mg tablet2.93USD tablet
Paroxetine hcl 30 mg tablet2.78USD tablet
Paroxetine hcl 20 mg tablet2.7USD tablet
Paroxetine hcl 10 mg tablet2.58USD tablet
Paxil 30 mg Tablet2.16USD tablet
Pms-Paroxetine 40 mg Tablet2.1USD tablet
Paxil 20 mg Tablet2.03USD tablet
Apo-Paroxetine 30 mg Tablet1.12USD tablet
Co Paroxetine 30 mg Tablet1.12USD tablet
Mylan-Paroxetine 30 mg Tablet1.12USD tablet
Novo-Paroxetine 30 mg Tablet1.12USD tablet
Phl-Paroxetine 30 mg Tablet1.12USD tablet
Pms-Paroxetine 30 mg Tablet1.12USD tablet
Ratio-Paroxetine 30 mg Tablet1.12USD tablet
Sandoz Paroxetine 30 mg Tablet1.12USD tablet
Apo-Paroxetine 20 mg Tablet1.05USD tablet
Co Paroxetine 20 mg Tablet1.05USD tablet
Mylan-Paroxetine 20 mg Tablet1.05USD tablet
Novo-Paroxetine 20 mg Tablet1.05USD tablet
Phl-Paroxetine 20 mg Tablet1.05USD tablet
Pms-Paroxetine 20 mg Tablet1.05USD tablet
Ratio-Paroxetine 20 mg Tablet1.05USD tablet
Sandoz Paroxetine 20 mg Tablet1.05USD tablet
Paxil 10 mg/5ml Suspension0.85USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2168829 No1997-12-162016-02-05Canada
CA2445678 No2009-11-242016-07-19Canada
US5789449 No1992-07-062009-07-06Us
US5811436 Yes1996-03-222016-03-22Us
US5872132 Yes1995-11-192015-11-19Us
US5874447 No1997-06-102017-06-10Us
US5900423 Yes1995-11-192015-11-19Us
US6063927 Yes1999-10-232019-10-23Us
US6080759 Yes1995-11-192015-11-19Us
US6121291 Yes1997-09-172017-09-17Us
US6133289 Yes1995-11-192015-11-19Us
US6172233 Yes1998-07-152018-07-15Us
US6548084 Yes1997-01-192017-01-19Us
US6703408 No2002-10-212022-10-21Us
US7229640 Yes1997-01-192017-01-19Us
US7598271 No2003-02-122023-02-12Us
US8658663 No2009-04-062029-04-06Us
US8946251 No2006-08-042026-08-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point147-150 °C (mesylate salt) FDA label
water solubility>1 g/mL (mesylate salt) Not Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00853 mg/mLALOGPS
logP3.1ALOGPS
logP3.15ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area39.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.02 m3·mol-1ChemAxon
Polarizability34.48 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-8900000000-0a273deac3c7836cdc76View in MoNA
References
Synthesis Reference

Charles M. Zepp, Yun Gao, Donald L. Heefner, “Method of preparing optically pure precursors of paroxetine.” U.S. Patent US5258517, issued January, 1976.

US5258517
General References
  1. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179 ]
  2. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999 Aug;175:120-6. [PubMed:10627793 ]
  3. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb;16(1):3-8. [PubMed:8834412 ]
  4. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B: Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998 Aug;18(4):274-81. [PubMed:9690692 ]
  5. Waldinger MD, Zwinderman AH, Olivier B: SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001 Dec;21(6):556-60. [PubMed:11763001 ]
External Links
ATC CodesN06AB05
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (299 KB)
MSDSDownload (51.2 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Paroxetine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Paroxetine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Paroxetine.
AbirateroneThe metabolism of Paroxetine can be decreased when combined with Abiraterone.
AcarboseParoxetine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Paroxetine.
AcenocoumarolParoxetine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Paroxetine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Paroxetine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Paroxetine.
AcetophenazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Paroxetine.
Acetylsalicylic acidParoxetine may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Paroxetine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Paroxetine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Paroxetine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Paroxetine.
AlbiglutideParoxetine may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Paroxetine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Paroxetine.
AlfentanilAlfentanil may increase the serotonergic activities of Paroxetine.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Paroxetine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Paroxetine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Paroxetine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Paroxetine.
AlogliptinParoxetine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Paroxetine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paroxetine.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Paroxetine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Paroxetine.
AmineptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Paroxetine.
AmiodaroneParoxetine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Paroxetine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Paroxetine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Paroxetine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Paroxetine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Paroxetine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Paroxetine.
AmoxapineParoxetine may increase the serotonergic activities of Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Paroxetine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Paroxetine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Paroxetine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Paroxetine.
AnagrelideParoxetine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Paroxetine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Paroxetine.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Paroxetine.
AprindineThe metabolism of Aprindine can be decreased when combined with Paroxetine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Paroxetine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Paroxetine.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Paroxetine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Paroxetine.
ArtemetherThe metabolism of Paroxetine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Paroxetine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Paroxetine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Paroxetine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Paroxetine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Paroxetine.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.
AtomoxetineThe metabolism of Paroxetine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Paroxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Paroxetine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Paroxetine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Paroxetine.
AzithromycinParoxetine may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Paroxetine.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Paroxetine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.
BedaquilineParoxetine may increase the QTc-prolonging activities of Bedaquiline.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Paroxetine.
BendroflumethiazideParoxetine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Paroxetine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Paroxetine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Paroxetine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Paroxetine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Paroxetine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Paroxetine.
BepridilThe metabolism of Bepridil can be decreased when combined with Paroxetine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Paroxetine.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Paroxetine.
BetaxololThe metabolism of Paroxetine can be decreased when combined with Betaxolol.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Paroxetine.
BezitramideBezitramide may increase the serotonergic activities of Paroxetine.
BifeprunoxThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Paroxetine.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Paroxetine.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Paroxetine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Paroxetine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Paroxetine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paroxetine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Paroxetine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.
BromocriptineParoxetine may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paroxetine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Paroxetine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Paroxetine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Paroxetine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Paroxetine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paroxetine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Paroxetine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Paroxetine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Paroxetine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Paroxetine.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Paroxetine.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Paroxetine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Paroxetine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Paroxetine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Paroxetine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Paroxetine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Paroxetine.
ButorphanolButorphanol may increase the serotonergic activities of Paroxetine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Paroxetine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paroxetine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Paroxetine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Paroxetine.
CanagliflozinParoxetine may increase the hypoglycemic activities of Canagliflozin.
CaptoprilThe metabolism of Captopril can be decreased when combined with Paroxetine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Paroxetine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Paroxetine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Paroxetine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Paroxetine.
CarfentanilCarfentanil may increase the serotonergic activities of Paroxetine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Paroxetine.
CariprazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.
CaroxazoneCaroxazone may increase the serotonergic activities of Paroxetine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Paroxetine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Paroxetine.
CelecoxibThe metabolism of Paroxetine can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Paroxetine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Paroxetine.
CeritinibParoxetine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Paroxetine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Paroxetine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Paroxetine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paroxetine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Paroxetine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Paroxetine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paroxetine.
ChloroquineParoxetine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Paroxetine can be decreased when combined with Chloroquine.
ChlorothiazideParoxetine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paroxetine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Paroxetine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paroxetine.
ChlorpropamideParoxetine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paroxetine.
ChlorthalidoneParoxetine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paroxetine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Paroxetine.
CholecalciferolThe metabolism of Paroxetine can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Paroxetine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Paroxetine.
CimetidineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Paroxetine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paroxetine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Paroxetine.
CiprofloxacinParoxetine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Paroxetine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Paroxetine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Paroxetine.
CitalopramThe metabolism of Paroxetine can be decreased when combined with Citalopram.
ClarithromycinParoxetine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Paroxetine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Paroxetine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Paroxetine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Paroxetine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Paroxetine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Paroxetine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Paroxetine.
ClomipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Paroxetine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Paroxetine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Paroxetine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Paroxetine.
ClotrimazoleThe metabolism of Paroxetine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Paroxetine.
CobicistatThe serum concentration of Paroxetine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Paroxetine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Paroxetine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Paroxetine.
CodeineCodeine may increase the serotonergic activities of Paroxetine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Paroxetine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Paroxetine.
CrizotinibParoxetine may increase the QTc-prolonging activities of Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclobenzaprine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Paroxetine.
CyproheptadineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Paroxetine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Paroxetine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Paroxetine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.
DapagliflozinParoxetine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paroxetine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.
DapoxetineParoxetine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe metabolism of Paroxetine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Paroxetine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Paroxetine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Paroxetine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Paroxetine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Paroxetine.
DelavirdineThe metabolism of Paroxetine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Paroxetine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.
DesipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.
DesmopressinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Paroxetine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Paroxetine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Paroxetine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paroxetine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Paroxetine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Paroxetine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paroxetine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Paroxetine.
DextromoramideDextromoramide may increase the serotonergic activities of Paroxetine.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Paroxetine.
DezocineDezocine may increase the serotonergic activities of Paroxetine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Paroxetine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Paroxetine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Paroxetine.
DicoumarolParoxetine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Paroxetine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Paroxetine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Paroxetine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Paroxetine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Paroxetine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Paroxetine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paroxetine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Paroxetine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Paroxetine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Paroxetine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Paroxetine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paroxetine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Paroxetine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Paroxetine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Paroxetine.
DisopyramideParoxetine may increase the hypoglycemic activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Paroxetine.
DofetilideParoxetine may increase the QTc-prolonging activities of Dofetilide.
DolasetronParoxetine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Paroxetine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Paroxetine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Paroxetine.
DopamineThe metabolism of Dopamine can be decreased when combined with Paroxetine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Paroxetine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Paroxetine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Paroxetine.
DoxepinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paroxetine.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine.
DPDPEDPDPE may increase the serotonergic activities of Paroxetine.
DronedaroneParoxetine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Paroxetine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Paroxetine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Paroxetine.
DulaglutideParoxetine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Paroxetine.
DuloxetineThe metabolism of Paroxetine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Paroxetine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Paroxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Paroxetine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Paroxetine.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Paroxetine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Paroxetine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paroxetine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Paroxetine.
EliglustatThe metabolism of Paroxetine can be decreased when combined with Eliglustat.
EmpagliflozinParoxetine may increase the hypoglycemic activities of Empagliflozin.
EncainideThe metabolism of Encainide can be decreased when combined with Paroxetine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Paroxetine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Paroxetine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Paroxetine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paroxetine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Paroxetine.
ErythromycinParoxetine may increase the QTc-prolonging activities of Erythromycin.
EscitalopramParoxetine may increase the serotonergic activities of Escitalopram.
EsmirtazapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Esmirtazapine.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Paroxetine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paroxetine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Paroxetine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Paroxetine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Paroxetine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paroxetine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Paroxetine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paroxetine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.
Ethyl biscoumacetateParoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paroxetine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Paroxetine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Paroxetine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Paroxetine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Paroxetine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Paroxetine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Paroxetine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.
EtoperidoneParoxetine may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Paroxetine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Paroxetine.
EtorphineEtorphine may increase the serotonergic activities of Paroxetine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Paroxetine.
ExenatideParoxetine may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Paroxetine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Paroxetine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Paroxetine.
FenfluramineFenfluramine may increase the serotonergic activities of Paroxetine.
FentanylFentanyl may increase the serotonergic activities of Paroxetine.
FentanylThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Paroxetine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Paroxetine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Paroxetine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Paroxetine.
FlecainideParoxetine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Paroxetine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Paroxetine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Paroxetine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Paroxetine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Paroxetine.
FluoxetineFluoxetine may increase the serotonergic activities of Paroxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Paroxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Paroxetine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paroxetine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Paroxetine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Paroxetine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Paroxetine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Paroxetine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Paroxetine.
FluvoxamineParoxetine may increase the serotonergic activities of Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Paroxetine.
FosamprenavirThe serum concentration of Paroxetine can be decreased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with Paroxetine resulting in a loss in efficacy.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Paroxetine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Paroxetine.
FrovatriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Paroxetine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Paroxetine.
Gadobenic acidParoxetine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Paroxetine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Paroxetine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Paroxetine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Paroxetine.
GemifloxacinParoxetine may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideParoxetine may increase the hypoglycemic activities of Gliclazide.
GlimepirideParoxetine may increase the hypoglycemic activities of Glimepiride.
GlipizideParoxetine may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Paroxetine.
GlyburideParoxetine may increase the hypoglycemic activities of Glyburide.
GoserelinParoxetine may increase the QTc-prolonging activities of Goserelin.
GranisetronParoxetine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Paroxetine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Paroxetine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Paroxetine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Paroxetine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Paroxetine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paroxetine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Paroxetine.
HalothaneThe metabolism of Halothane can be decreased when combined with Paroxetine.
HeroinHeroin may increase the serotonergic activities of Paroxetine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Paroxetine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Paroxetine.
HydrochlorothiazideParoxetine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.
HydrocodoneHydrocodone may increase the serotonergic activities of Paroxetine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Paroxetine.
HydroflumethiazideParoxetine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Paroxetine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Paroxetine.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Paroxetine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Paroxetine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Paroxetine.
IbutilideParoxetine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Paroxetine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Paroxetine.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Paroxetine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Paroxetine.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Paroxetine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Paroxetine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Paroxetine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Paroxetine.
IndalpineParoxetine may increase the serotonergic activities of Indalpine.
IndapamideParoxetine may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Paroxetine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Paroxetine.
IndinavirThe metabolism of Paroxetine can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Paroxetine.
Insulin AspartParoxetine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirParoxetine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineParoxetine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineParoxetine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanParoxetine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproParoxetine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I 123Paroxetine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Paroxetine.
IproclozideIproclozide may increase the serotonergic activities of Paroxetine.
IproniazidIproniazid may increase the serotonergic activities of Paroxetine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Paroxetine.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Paroxetine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Paroxetine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Paroxetine.
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Paroxetine.
IsoniazidThe metabolism of Paroxetine can be decreased when combined with Isoniazid.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Paroxetine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Paroxetine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paroxetine.
KetamineThe metabolism of Ketamine can be decreased when combined with Paroxetine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Paroxetine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Paroxetine.
KetobemidoneKetobemidone may increase the serotonergic activities of Paroxetine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Paroxetine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Paroxetine.
KetoconazoleThe metabolism of Paroxetine can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Paroxetine.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Paroxetine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Paroxetine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paroxetine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Paroxetine.
LanreotideParoxetine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Paroxetine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Paroxetine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Paroxetine.
LenvatinibParoxetine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideParoxetine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Paroxetine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Paroxetine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Paroxetine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paroxetine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Paroxetine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Paroxetine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Paroxetine.
LevofloxacinParoxetine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Paroxetine.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Paroxetine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Paroxetine.
LevorphanolLevorphanol may increase the serotonergic activities of Paroxetine.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paroxetine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Paroxetine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Paroxetine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Paroxetine.
LinezolidLinezolid may increase the serotonergic activities of Paroxetine.
LinezolidThe risk or severity of adverse effects can be increased when Paroxetine is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Paroxetine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Paroxetine.
LiraglutideParoxetine may increase the hypoglycemic activities of Liraglutide.
LisurideThe metabolism of Lisuride can be decreased when combined with Paroxetine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Paroxetine.
LofentanilLofentanil may increase the serotonergic activities of Paroxetine.
LomustineThe metabolism of Lomustine can be decreased when combined with Paroxetine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Paroxetine.
LopinavirParoxetine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Paroxetine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Paroxetine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Paroxetine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.
LorcaserinThe metabolism of Paroxetine can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Paroxetine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paroxetine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Paroxetine.
Lu AA21004Paroxetine may increase the serotonergic activities of Lu AA21004.
LumefantrineParoxetine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Paroxetine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Paroxetine.
MalathionThe metabolism of Malathion can be decreased when combined with Paroxetine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Paroxetine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Paroxetine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Paroxetine.
MebanazineMebanazine may increase the serotonergic activities of Paroxetine.
MecaserminParoxetine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Paroxetine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Paroxetine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Paroxetine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Paroxetine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Paroxetine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paroxetine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Paroxetine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Paroxetine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.
MetforminParoxetine may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the serotonergic activities of Paroxetine.
MethadoneParoxetine may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Paroxetine.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Paroxetine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Paroxetine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Paroxetine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Paroxetine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Paroxetine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Paroxetine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Paroxetine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.
MethyclothiazideParoxetine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueParoxetine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Paroxetine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paroxetine.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Paroxetine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Paroxetine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Paroxetine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Paroxetine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Paroxetine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.
MetolazoneParoxetine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Paroxetine.
MetoprololThe metabolism of Paroxetine can be decreased when combined with Metoprolol.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Paroxetine.
MianserinThe metabolism of Mianserin can be decreased when combined with Paroxetine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Paroxetine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Paroxetine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Paroxetine.
MifepristoneParoxetine may increase the hypoglycemic activities of Mifepristone.
MiglitolParoxetine may increase the hypoglycemic activities of Miglitol.
MilnacipranParoxetine may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Paroxetine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Paroxetine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Paroxetine.
MirabegronThe metabolism of Paroxetine can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mirtazapine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Paroxetine.
MoclobemideMoclobemide may increase the serotonergic activities of Paroxetine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Paroxetine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Paroxetine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Paroxetine.
MorphineMorphine may increase the serotonergic activities of Paroxetine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Paroxetine.
MoxifloxacinParoxetine may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paroxetine.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Paroxetine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Paroxetine.
NalbuphineNalbuphine may increase the serotonergic activities of Paroxetine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Paroxetine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Paroxetine.
NaratriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Naratriptan.
NateglinideParoxetine may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Paroxetine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paroxetine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Paroxetine.
NetupitantThe metabolism of Netupitant can be decreased when combined with Paroxetine.
NevirapineThe metabolism of Paroxetine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Paroxetine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Paroxetine.
NicardipineThe metabolism of Paroxetine can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Paroxetine.
NicotineThe metabolism of Nicotine can be decreased when combined with Paroxetine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Paroxetine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Paroxetine.
NilotinibThe metabolism of Paroxetine can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Paroxetine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Paroxetine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Paroxetine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Paroxetine.
NormethadoneNormethadone may increase the serotonergic activities of Paroxetine.
NortriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.
OctamoxinOctamoxin may increase the serotonergic activities of Paroxetine.
OctreotideParoxetine may increase the hypoglycemic activities of Octreotide.
OfloxacinParoxetine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Paroxetine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Paroxetine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Paroxetine.
OpiumOpium may increase the serotonergic activities of Paroxetine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paroxetine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Paroxetine.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Paroxetine.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Paroxetine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Paroxetine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Paroxetine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paroxetine.
OxycodoneOxycodone may increase the serotonergic activities of Paroxetine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Paroxetine.
OxymorphoneOxymorphone may increase the serotonergic activities of Paroxetine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Paroxetine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Paroxetine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Paroxetine.
PalonosetronPalonosetron may increase the serotonergic activities of Paroxetine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Paroxetine.
PanobinostatParoxetine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Paroxetine can be decreased when combined with Panobinostat.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Paroxetine.
PargylinePargyline may increase the serotonergic activities of Paroxetine.
PasireotideParoxetine may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Paroxetine.
PentamidineParoxetine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Paroxetine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paroxetine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Paroxetine.
PerflutrenParoxetine may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Paroxetine.
PermethrinThe metabolism of Permethrin can be decreased when combined with Paroxetine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Paroxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paroxetine.
PethidinePethidine may increase the serotonergic activities of Paroxetine.
PethidineThe metabolism of Pethidine can be decreased when combined with Paroxetine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Paroxetine.
PhenelzinePhenelzine may increase the serotonergic activities of Paroxetine.
PhenelzineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Paroxetine.
PhenindioneParoxetine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Paroxetine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paroxetine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Paroxetine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Paroxetine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Paroxetine.
PhenprocoumonParoxetine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Paroxetine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Paroxetine.
PimozideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Paroxetine.
PioglitazoneParoxetine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Paroxetine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Paroxetine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Paroxetine.
PirlindolePirlindole may increase the serotonergic activities of Paroxetine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Paroxetine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Paroxetine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Paroxetine.
PolythiazideParoxetine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Paroxetine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Paroxetine.
PractololThe serum concentration of Practolol can be increased when it is combined with Paroxetine.
PramlintideParoxetine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Paroxetine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Paroxetine.
PravastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Paroxetine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Paroxetine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Paroxetine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Paroxetine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Paroxetine.
PrimaquineParoxetine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Paroxetine.
ProcainamideParoxetine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Paroxetine.
ProcarbazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paroxetine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Paroxetine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Paroxetine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Paroxetine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Paroxetine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Paroxetine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Paroxetine.
PropericiazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Paroxetine.
PropofolThe metabolism of Propofol can be decreased when combined with Paroxetine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Paroxetine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Paroxetine.
ProtriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Paroxetine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Paroxetine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Paroxetine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Paroxetine.
QuinethazoneParoxetine may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Paroxetine.
QuinidineThe metabolism of Paroxetine can be decreased when combined with Quinidine.
QuinineParoxetine may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Paroxetine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Paroxetine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Paroxetine.
RanolazineThe metabolism of Paroxetine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Paroxetine.
RasagilineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Paroxetine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Paroxetine.
RepaglinideParoxetine may increase the hypoglycemic activities of Repaglinide.
repinotanThe metabolism of repinotan can be decreased when combined with Paroxetine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paroxetine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Paroxetine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Paroxetine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Paroxetine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paroxetine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Paroxetine.
RitonavirThe metabolism of Paroxetine can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Paroxetine.
RizatriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Rizatriptan.
RolapitantThe metabolism of Paroxetine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Paroxetine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Paroxetine.
RopiniroleThe metabolism of Paroxetine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Paroxetine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Paroxetine.
RosiglitazoneParoxetine may increase the hypoglycemic activities of Rosiglitazone.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Paroxetine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Paroxetine.
SafrazineSafrazine may increase the serotonergic activities of Paroxetine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Paroxetine.
SaquinavirParoxetine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinParoxetine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.
SelegilineSelegiline may increase the serotonergic activities of Paroxetine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Paroxetine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Paroxetine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Paroxetine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Paroxetine.
SertralineThe metabolism of Paroxetine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paroxetine.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Paroxetine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Paroxetine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Paroxetine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Paroxetine.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Paroxetine.
SitagliptinParoxetine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Paroxetine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Paroxetine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Paroxetine.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Paroxetine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Paroxetine.
SparteineThe metabolism of Sparteine can be decreased when combined with Paroxetine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Paroxetine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Paroxetine.
SufentanilSufentanil may increase the serotonergic activities of Paroxetine.
SulfadiazineParoxetine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleParoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleParoxetine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Paroxetine.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Paroxetine.
SunitinibParoxetine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Paroxetine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Paroxetine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Paroxetine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.
TapentadolTapentadol may increase the serotonergic activities of Paroxetine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Paroxetine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Paroxetine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Paroxetine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Paroxetine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Paroxetine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Paroxetine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Paroxetine.
TelavancinParoxetine may increase the QTc-prolonging activities of Telavancin.
TelithromycinParoxetine may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Paroxetine.
TemazepamThe metabolism of Temazepam can be decreased when combined with Paroxetine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Paroxetine.
TerbinafineThe metabolism of Paroxetine can be decreased when combined with Terbinafine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Paroxetine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Paroxetine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Paroxetine.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Paroxetine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Paroxetine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Paroxetine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Paroxetine.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paroxetine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Paroxetine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paroxetine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Paroxetine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Paroxetine.
ThioproperazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Paroxetine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Paroxetine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Paroxetine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.
TianeptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tianeptine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Paroxetine.
TiclopidineThe metabolism of Paroxetine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Paroxetine.
TimololThe serum concentration of Timolol can be increased when it is combined with Paroxetine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Paroxetine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Paroxetine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Paroxetine.
TolazamideParoxetine may increase the hypoglycemic activities of Tolazamide.
TolbutamideParoxetine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.
ToloxatoneToloxatone may increase the serotonergic activities of Paroxetine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Paroxetine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Paroxetine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Paroxetine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Paroxetine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Paroxetine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Paroxetine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Paroxetine.
TramadolTramadol may increase the serotonergic activities of Paroxetine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Paroxetine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Paroxetine.
TranylcypromineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Paroxetine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Paroxetine.
TrazodoneParoxetine may increase the serotonergic activities of Trazodone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Paroxetine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.
TrichlormethiazideParoxetine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine.
TrimipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Paroxetine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Paroxetine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Paroxetine.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Paroxetine.
VandetanibParoxetine may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Paroxetine.
VemurafenibParoxetine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Paroxetine.
VenlafaxineThe metabolism of Paroxetine can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Paroxetine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.
VilazodoneParoxetine may increase the serotonergic activities of Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Paroxetine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Paroxetine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Paroxetine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Paroxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Paroxetine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Paroxetine.
WarfarinParoxetine may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Paroxetine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Paroxetine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Paroxetine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Paroxetine.
ZimelidineParoxetine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Paroxetine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Paroxetine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paroxetine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Paroxetine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Paroxetine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paroxetine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Paroxetine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Paroxetine.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. [PubMed:10869387 ]
  2. Preuss UW, Soyka M, Bahlmann M, Wenzel K, Behrens S, de Jonge S, Kruger M, Bondy B: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Psychiatry Res. 2000 Sep 25;96(1):51-61. [PubMed:10980326 ]
  3. Haughey HM, Fleckenstein AE, Metzger RR, Hanson GR: The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem. 2000 Oct;75(4):1608-17. [PubMed:10987842 ]
  4. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90. [PubMed:11027924 ]
  5. Wihlback AC, Sundstrom-Poromaa I, Allard P, Mjorndal T, Spigset O, Backstrom T: Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol. 2001 Sep;98(3):450-7. [PubMed:11530128 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Rubin RT: Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry. 2000 Nov 1;48(9):954-6. [PubMed:11203183 ]
  2. Gilmor ML, Owens MJ, Nemeroff CB: Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002 Oct;159(10):1702-10. [PubMed:12359676 ]
  3. Nemeroff CB, Owens MJ: Neuropharmacology of paroxetine. Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18. [PubMed:14566196 ]
  4. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Bixo M, Allard P, Backstrom T, Mjorndal T, Nyberg S, Spigset O, Sundstrom-Poromaa I: Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. 2001 Aug;26(6):551-64. [PubMed:11403977 ]
  2. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001 Jan;158(1):78-85. [PubMed:11136637 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. [PubMed:9333110 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 30, 2016 03:27